Company intelligence / Profile preview

Rapafusyn Pharmaceuticals

Baltimore, Maryland, United Statesrapafusyn.com ↗

Ownership: Private
Employees: ~12
Development stage: Preclinical

Overview

Rapafusyn has demonstrated the ability of its RapaGlue™ platform to rapidly generate novel non-degrading molecular glues that form ternary complexes with disease-relevant proteins. These compounds have shown promise in modulating previously undruggable protein-protein interactions and other challenging intracellular or membrane targets. All programs remain at the preclinical stage; no clinical results have been reported as of May 2025.[2][6][9]

Therapeutic areas: OncologyImmunologyCardiovascular
Modalities: Non-degrading molecular glues (macrocyclic peptides)[1][2]Small molecules (macrocycles)[3]
Industry: Biotech

Drug pipeline

8 assets

RAP-0001

Preclinical

7 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Rapafusyn Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rapafusyn Pharmaceuticals.

Explore the full profile